

Antonio Calles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3615289/publications.pdf>

Version: 2024-02-01

94
papers

2,393
citations

218677

26
h-index

214800

47
g-index

96
all docs

96
docs citations

96
times ranked

4919
citing authors

#	ARTICLE	IF	CITATIONS
1	Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics, 2022, , .	2.1	7
2	A phase 1/2 trial of lurbinectedin (L) in combination with pembrolizumab (P) in relapsed small cell lung cancer (SCLC): The LUPER study.. Journal of Clinical Oncology, 2022, 40, 8581-8581.	1.6	2
3	Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations. Molecular Oncology, 2021, 15, 27-42.	4.6	15
4	Steroid Use Independently Predicts for Poor Outcomes in Patients With Advanced NSCLC and High PD-L1 Expression Receiving First-Line Pembrolizumab Monotherapy. Clinical Lung Cancer, 2021, 22, e180-e192.	2.6	15
5	Abstract S12-04: COVID-19 disease in patients with lung cancer in Spain: GRAVID Lung Cancer Patients Disease (GRAVID study). , 2021, , .		0
6	Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis. Journal of the American College of Cardiology, 2021, 77, 1503-1516.	2.8	97
7	Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network. ESMO Open, 2021, 6, 100104.	4.5	15
8	Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring. ESMO Open, 2021, 6, 100117.	4.5	37
9	Lung cancer patients with COVID-19 in Spain: GRAVID study. Lung Cancer, 2021, 157, 109-115.	2.0	24
10	Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110196.	3.2	27
11	MO01.42 Myelopreservation with Trilaciclib Regardless of Risk of Chemotherapy-Induced Febrile Neutropenia and/or Anemia or Red Blood Cell Transfusions. Journal of Thoracic Oncology, 2021, 16, S33-S34.	1.1	1
12	Efficacy and safety of immune checkpoint inhibitor immunotherapy in elderly cancer patients. Clinical and Translational Oncology, 2020, 22, 555-562.	2.4	14
13	From presentation to paper: Gender disparities in oncological research. International Journal of Cancer, 2020, 146, 3011-3021.	5.1	9
14	Outcomes of COVID-19 in Patients With Lung Cancer Treated in a Tertiary Hospital in Madrid. Frontiers in Oncology, 2020, 10, 1777.	2.8	28
15	Efficacy of Pembrolizumab Monotherapy in Patients With or Without Brain Metastases From Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression $\geq 50\%$. Journal of Immunotherapy, 2020, 43, 299-306.	2.4	18
16	Standardizing Health Outcomes for Lung Cancer. Adaptation of the International Consortium for Health Outcomes Measurement Set to the Spanish Setting. Frontiers in Oncology, 2020, 10, 1645.	2.8	7
17	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1 refractory tumors. Science Translational Medicine, 2020, 12, .	12.4	51
18	Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, 372-384.	3.8	64

#	ARTICLE	IF	CITATIONS
19	Nephrotic syndrome in a 60-year-old man. <i>Journal of Clinical Pathology</i> , 2020, 73, e3-e3.	2.0	0
20	Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 1041-1048.	2.4	7
21	Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score $\geq 50\%$ treated with front-line pembrolizumab. <i>Acta Oncologica</i> , 2020, 59, 1058-1063.	1.8	31
22	Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. <i>Clinical Lung Cancer</i> , 2020, 21, 428-436.e2.	2.6	14
23	Abstract PO-036: Safety outcomes of resuming anticancer treatment in patients with lung cancer affected by COVID-19 illness. , 2020, , .		1
24	Poor performance status and front-line pembrolizumab in advanced non-small-cell lung cancer (NSCLC) patients with PD-L1 $> 50\%$. <i>Journal of Clinical Oncology</i> , 2020, 38, e21651-e21651.	1.6	4
25	Comprehensive genomic profile by Foundation Medicine test in guiding routine decisions for second-line treatment in advanced non-small cell breast cancer (NSCLC): Preliminary results of lung-ONE study.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21555-e21555.	1.6	0
26	Abstract PO-021: Impact of COVID-19 in continuity of cancer treatment for lung cancer patients. , 2020, , .		0
27	Abstract PO-031: Outcomes of COVID-19 in patients with lung cancer treated in a tertiary hospital in Madrid. , 2020, , .		1
28	Pembrolizumab frontline monotherapy in patients with NSCLC and high PD-L1 expression: Real-world data from a European Cohort with focus on subgroups of interest. <i>Annals of Oncology</i> , 2019, 30, v622-v623.	1.2	0
29	Observational Prospective Study to Determine the Evolution of the Symptomatic Profile of Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients and Its Relation to the Control of the Disease. <i>Advances in Therapy</i> , 2019, 36, 1497-1508.	2.9	4
30	The role of immunotherapy in small cell lung cancer. <i>Clinical and Translational Oncology</i> , 2019, 21, 961-976.	2.4	81
31	A Phase I Dose-Escalation Study of Veliparib Combined with Carboplatin and Etoposide in Patients with Extensive-Stage Small Cell Lung Cancer and Other Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 496-505.	7.0	33
32	For Whom the Cell Tolls? Intratumoral Treatment Links Innate and Adaptive Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 1127-1129.	7.0	4
33	Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 $\geq 50\%$ who progress on first-line immunotherapy: real-world data from a European cohort. <i>Journal of Thoracic Disease</i> , 2019, 11, 4972-4981.	1.4	35
34	From presentation to paper: Gender disparities in oncological research.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10523-10523.	1.6	0
35	Abstract 3783: Effective MEK inhibitor combinations to target tumor heterogeneity in EGFR mutant transformed SCLC. , 2019, , .		0
36	Abstract 3783: Effective MEK inhibitor combinations to target tumor heterogeneity in EGFR mutant transformed SCLC. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
37	159P Clinical activity of afatinib in a cohort of patients with lung adenocarcinoma harbouring uncommon EGFR mutations: A Spanish retrospective multicentre study. <i>Journal of Thoracic Oncology</i> , 2018, 13, S95-S96.	1.1	1
38	Genomic Correlates of Response to Everolimus in Aggressive Radioiodine-refractory Thyroid Cancer: A Phase II Study. <i>Clinical Cancer Research</i> , 2018, 24, 1546-1553.	7.0	86
39	Aligning digital CD8 ⁺ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. <i>Histopathology</i> , 2018, 72, 270-284.	2.9	17
40	P1.15-03 Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC from Real-World Data (RWD). <i>Journal of Thoracic Oncology</i> , 2018, 13, S612.	1.1	0
41	Intratumoral BO-112, a double-stranded RNA (dsRNA), alone and in combination with systemic anti-PD-1 in solid tumors. <i>Annals of Oncology</i> , 2018, 29, viii732.	1.2	8
42	A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2018, 104, 1-8.	2.8	10
43	Atezolizumab Treatment of Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018, 379, 1187-1188.	27.0	10
44	Oncology Patient Interest in the Use of New Technologies to Manage Their Disease: Cross-Sectional Survey. <i>Journal of Medical Internet Research</i> , 2018, 20, e11006.	4.3	33
45	Abstract 955: Combined inhibition of MEK and mTOR pathways is effective in NRAS Q61K mutant small cell lung cancer. , 2018, , .		0
46	Long-term survival in advanced non-squamous NSCLC patients treated with first-line bevacizumab-based therapy. <i>Clinical and Translational Oncology</i> , 2017, 19, 219-226.	2.4	3
47	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017, 23, 5406-5415.	7.0	29
48	Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. <i>Cancer Research</i> , 2017, 77, 2712-2721.	0.9	110
49	P2.01-064 Molecular Context of Immune Microenvironment in Early-Stage Lung Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S825-S826.	1.1	0
50	Genomic Heterogeneity and Exceptional Response to Dual Pathway Inhibition in Anaplastic Thyroid Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2367-2373.	7.0	24
51	Validation of the Royal Marsden Hospital (RMH) prognostic score on an enriched early treatment line cohort for phase I trial patients. <i>Annals of Oncology</i> , 2017, 28, v135.	1.2	0
52	Safety and immunobiological activity of intratumoral (IT) double-stranded RNA (dsRNA) BO-112 in solid malignancies: First in human clinical trial. <i>Annals of Oncology</i> , 2017, 28, v612.	1.2	2
53	Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8530-8530.	1.6	3
54	CREBBP alterations found in extreme responders to PD-1 inhibition in patients (pts) with refractory solid tumors treated in a phase 1 trials unit. <i>Annals of Oncology</i> , 2016, 27, vi23.	1.2	0

#	ARTICLE	IF	CITATIONS
55	Impact of tumor heregulin mRNA expression on outcome of patients with advanced/metastatic squamous NSCLC treated with lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with erlotinib. <i>Annals of Oncology</i> , 2016, 27, vi117.	1.2	0
56	Phase Ib study of afatinib plus standard-dose cetuximab in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2016, 69, S139-S140.	2.8	1
57	Pharmacogenetics and pharmacogenomics as tools in cancer therapy. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 25-34.	0.6	23
58	Abstract LB-227: Truncal activating MAPK and PI3K pathway alterations and exceptional response to dual pathway inhibition in anaplastic thyroid cancer. , 2016, , .		0
59	Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1726-1735.	1.1	208
60	Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2. <i>Cancer Research</i> , 2015, 75, 3139-3146.	0.9	30
61	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2462-2470.	7.0	51
62	Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small cell lung cancer cell lines. <i>Molecular Oncology</i> , 2015, 9, 260-269.	4.6	51
63	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2015, 33, 710-719.	2.6	24
64	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2851-2860.	7.0	96
65	A Functional Landscape of Resistance to ALK Inhibition in Lung Cancer. <i>Cancer Cell</i> , 2015, 27, 397-408.	16.8	150
66	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase Ib study. <i>Targeted Oncology</i> , 2015, 10, 111-123.	3.6	158
67	Abstract 1451: Modeling patient-derived lung cancer in mice: Preclinical tool for drug development. , 2015, , .		0
68	Genomic Changes in Lung Cancer Patients with Multiple Lung Relapses. <i>Annals of Oncology</i> , 2014, 25, iv412.	1.2	0
69	Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. <i>British Journal of Cancer</i> , 2014, 111, 2058-2066.	6.4	31
70	Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 644-652.	2.6	1
71	Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer. <i>Investigational New Drugs</i> , 2014, 32, 955-968.	2.6	55
72	Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. <i>Clinical Cancer Research</i> , 2014, 20, 2476-2484.	7.0	140

#	ARTICLE	IF	CITATIONS
73	Differential expression of LKB1, PD-L1, and PD-L2 in KRAS-mutant non-small cell lung cancer in never-smokers.. Journal of Clinical Oncology, 2014, 32, 8032-8032.	1.6	5
74	Primary Human Non-Small Cell Lung and Pancreatic Tumorgraft Models Utility and Applications in Drug Discovery and Tumor Biology. Current Protocols in Pharmacology, 2013, 61, Unit 14.26.	4.0	21
75	Abstract 3363: Pharmacodynamic (PD) assessment of drug activity in tumor tissue from patients (pts) enrolled in a Phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual action antibody, in pts with locally advanced or metastatic epithelial tumors.. , 2013, , .		2
76	Phase I clinical trials attrition related to central molecular prescreening.. Journal of Clinical Oncology, 2013, 31, 2600-2600.	1.6	6
77	Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. Journal of Clinical Oncology, 2012, 30, e45-e48.	1.6	79
78	Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer, 2012, 12, 260.	2.6	110
79	Abstract 5587: Phase I study of PM00104 in combination with carboplatin in patients (pts) with advanced solid tumors. , 2012, , .		1
80	Abstract CT-08: A Phase 1 study of MEHD7945A (MEHD), a first-in-class EGFR/HER3 dual action antibody, in patients (pts) with locally advanced or metastatic epithelial tumors. , 2012, , .		1
81	A phase I study of MEHD7945A (MEHD), a first-in-class HER3/EGFR dual-action antibody, in patients (pts) with refractory/recurrent epithelial tumors: Expansion cohorts.. Journal of Clinical Oncology, 2012, 30, 2568-2568.	1.6	9
82	Phase Ib study of CNTO 888 (anti-CCL 2) in combination with chemotherapies for treatment of patients with solid tumors.. Journal of Clinical Oncology, 2012, 30, 3059-3059.	1.6	0
83	Long-term survivors with advanced nonsquamous non-small cell lung cancer (nsNSCLC) treated with first-line (1L) chemotherapy (CT) plus bevacizumab (B) and maintenance (mtc) B.. Journal of Clinical Oncology, 2012, 30, e18055-e18055.	1.6	0
84	Feasibility to obtain a chemogram in circulating tumorigenic cells to guide further treatments in refractory solid tumors.. Journal of Clinical Oncology, 2012, 30, 3066-3066.	1.6	1
85	Human pharmacokinetic (PK) characterization of the novel dual-action anti-HER3/EGFR antibody MEHD7945A (MEHD) in patients with refractory/recurrent epithelial tumors.. Journal of Clinical Oncology, 2012, 30, 2567-2567.	1.6	1
86	Integrated next-generation sequencing and patient-derived xenografts to personalized cancer treatment.. Journal of Clinical Oncology, 2012, 30, 3068-3068.	1.6	0
87	Phase I study of PM00104 in combination with carboplatin (C) in patients (pts) with advanced solid tumors.. Journal of Clinical Oncology, 2011, 29, e13085-e13085.	1.6	1
88	Abstract A91: A phase I dose-escalation study of bosutinib plus capecitabine in selected advanced solid tumors.. , 2011, , .		0
89	Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. Clinical and Translational Oncology, 2010, 12, 310-314.	2.4	5
90	Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 891-910.	1.1	48

#	ARTICLE	IF	CITATIONS
91	Adjuvant chemotherapy for early-stage non-small-cell lung cancer. Single-centre experience and literature review. <i>Clinical and Translational Oncology</i> , 2008, 10, 560-571.	2.4	4
92	Maintenance treatment in metastatic breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1907-1912.	2.4	39
93	Bevacizumab in Combination with Metronomic Chemotherapy in Patients with Anthracycline- and Taxane-Refractory Breast Cancer. <i>Journal of Chemotherapy</i> , 2008, 20, 632-639.	1.5	59
94	Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	0